SEC Comment Letter 0000000000-23-012625 to Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc.
Date: Nov. 17, 2023 · CIK: 0001716947 · Accession: 0000000000-23-012625
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275456
Letter
United States securities and exchange commission logo November 17, 2023 Lynn Kirkpatrick Chief Executive Officer Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, CA 92037 Re:Ensysce Biosciences, Inc. Registration Statement of Form S-1 Filed November 9, 2023 File No. 333-275456 Dear Lynn Kirkpatrick: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Eric D. Kline
Show Raw Text
United States securities and exchange commission logo
November 17, 2023
Lynn Kirkpatrick
Chief Executive Officer
Ensysce Biosciences, Inc.
7946 Ivanhoe Avenue, Suite 201
La Jolla, CA 92037
Re:Ensysce Biosciences, Inc.
Registration Statement of Form S-1
Filed November 9, 2023
File No. 333-275456
Dear Lynn Kirkpatrick:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Eric D. Kline